Abstract
This chapter compares laser coagulation with anti-VEGF treatment and shows in detail the advantages and disadvantages of each treatment method.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, Chen Y, Yu W, Li X. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology. 2017;124(3):408–9.
Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;1555(6):1119–24.
Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register. Br J Ophthalmol. 2016;100(12):1656–61.
Hu J, Blair MP, Shapiro MJ, Lichetnstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000–6.
Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22(1):61–65.e1.
Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218–26.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845–55.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Spandau, U., Kim, S.J. (2019). Lasercoagulation or Anti-VEGF: What Is the Better Treatment?. In: Pediatric Retinal Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13701-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-13701-4_10
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13700-7
Online ISBN: 978-3-030-13701-4
eBook Packages: MedicineMedicine (R0)